

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

PROFIT WARNING

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, based on unaudited consolidated financial statements currently available to the Board, the Group has recorded a loss attributable to equity shareholders of the Company for the twelve months ended 31 December 2020 of between US\$188 million and US\$203 million, as compared with a profit of approximately US\$46.3 million for the same period of last year. This change was principally attributable to: (i) the year-on-year decrease in the sales revenue of implantable devices due to the significant decline in the number of clinical consultation and surgery brought on by the COVID-19 pandemic; (ii) adjustments to provision for price subsidy with reference to the 2021 implementation price for stent products that have been sold but not yet implanted in the channels due to centralized procurement policy for coronary stents of the PRC in the fourth quarter; (iii) the incentive shares granted to certain employees (including an executive director) pursuant to the Share Award Scheme of the Group during the reporting period; and (iv) lack of the one-time investment gain on partial disposal of equity interests in Shanghai MicroPort EP MedTech Co., Ltd. for the same period of last year.

As at the date of this announcement, the Company is still in the process of preparing and completing the annual results of the Group for the twelve months ended 31 December 2020 (the “**2020 Annual Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the Company’s shares and securities and potential investors are advised to read the Company’s announcement for the 2020 Annual Results carefully, which is expected to be published before the end of March 2021. Holders of the Company’s shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 26 February 2021

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*